 |
|
|
|
2005 News Releases
| DATE |
TITLE |
| October 27, 2005 |
Pozen Reports Third Quarter 2005 Results; Trexima(TM) NDA Accepted for Filing by FDA in October |
| October 13, 2005 |
POZEN Announces October 27 Webcast of Third Quarter Results |
| October 11, 2005 |
GlaxoSmithKline and POZEN Announce Trexima(TM) (Sumatriptan Succinate and Naproxen Sodium) New Drug Application Accepted for Review by FDA |
| September 13, 2005 |
Pozen to Present at UBS Global Life Sciences Conference |
| August 16, 2005 |
POZEN Receives Patent on Novel Pain Management/GI Combination Product; Company to Present Study Data at ACG Annual Meeting in November 2005 |
| August 08, 2005 |
POZEN Submits New Drug Application for Trexima(TM) (Sumatriptan Succinate and Naproxen Sodium) for the Acute Treatment of Migraine |
| August 05, 2005 |
POZEN Provides Results of FDA Advisory Committee Meeting on MT 100(TM) (Naproxen Sodium and Metoclopramide Hydrochloride) |
| July 28, 2005 |
POZEN Reports Second Quarter 2005 Results; Trexima(TM) NDA on Track for Q3 2005 Submission |
| July 14, 2005 |
POZEN Announces July 28 Webcast of Second Quarter Results |
| June 29, 2005 |
FDA Sets August 4, 2005 for Advisory Committee Meeting to Consider Tardive Dyskinesia Risk with MT 100 |
| June 23, 2005 |
POZEN Names Dr. William Kelce as Vice President, Pre-Clinical Development |
| June 21, 2005 |
POZEN Names Lisa Zimmerman Vice President, Quality Assurance |
| May 25, 2005 |
POZEN to Present at Friedman Billings Ramsey 9th Annual Growth Conference |
| May 16, 2005 |
POZEN to Present at UBS Global Pharmaceuticals Conference |
| April 28, 2005 |
POZEN Reports First Quarter 2005 Results; Trexima NDA Scheduled for 3Q 2005; Notice of Allowance Received for New Patent Application Describing Gastroprotective NSAID Products |
| April 21, 2005 |
POZEN Hits All Primary Endpoints in Second Phase III Pivotal Trial for Trexima; NDA Submission Scheduled for 3Q 2005 |
| April 14, 2005 |
POZEN Announces April 28 Webcast of First Quarter 2005 Results |
| February 28, 2005 |
POZEN Reports Fourth Quarter and Year End 2004 Results; Completes First Trexima Phase III Study |
| February 25, 2005 |
Pozen to Present at Wells Fargo Securities Health Care Conference |
| February 18, 2005 |
POZEN Reports Fourth Quarter and Full-Year 2004 Results |
| February 07, 2005 |
POZEN To Present at NCINVEST2005 Investor Conference |
| January 26, 2005 |
POZEN Receives Positive News on MT 100 in the U.K. |
| January 25, 2005 |
European Patent Issued to POZEN for Treatment of Migraine |
| January 20, 2005 |
Pozen to Present at Piper Jaffray Health Care Conference |
| January 12, 2005 |
POZEN Inc. Adopts Stockholder Rights Plan |
|
|
|
|
|
|
 |
